BTIG initiated coverage of Hyperfine (HYPR) with a Buy rating and $2 price target The company’s Swoop System enables point-of-care brain MRI at the bedside, expanding access to MRI imaging by eliminating the need for a shielded room, specialized staff, and patient transport, and the next-generation Swoop V2, cleared in May 2025, paired with the 11th-generation Optive AI software release in December 2025, offers a significant step forward in image quality and clinical utility, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HYPR:
- Hyperfine receives CE Marking, UK Conformity Assessment approval
- Hyperfine’s Portable MRI Trial Update Puts Contrast Imaging in the Spotlight
- Horizon Technology provides $40M loan facility to Hyperfine
- Hyperfine Inc. Exposed to Rising Credit Risk as Delayed Customer Payments Threaten Cash Flow and Financial Stability
- Hyperfine Inc. Earnings Call Signals Commercial Breakthrough
